GB2194145A - Saliva replacement formulations - Google Patents

Saliva replacement formulations Download PDF

Info

Publication number
GB2194145A
GB2194145A GB08703511A GB8703511A GB2194145A GB 2194145 A GB2194145 A GB 2194145A GB 08703511 A GB08703511 A GB 08703511A GB 8703511 A GB8703511 A GB 8703511A GB 2194145 A GB2194145 A GB 2194145A
Authority
GB
United Kingdom
Prior art keywords
formulation according
formulation
saliva
preservative
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08703511A
Other versions
GB2194145B (en
GB8703511D0 (en
Inventor
Martin Francis Donnellan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CATCHGATE Ltd
Original Assignee
CATCHGATE Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CATCHGATE Ltd filed Critical CATCHGATE Ltd
Publication of GB8703511D0 publication Critical patent/GB8703511D0/en
Publication of GB2194145A publication Critical patent/GB2194145A/en
Application granted granted Critical
Publication of GB2194145B publication Critical patent/GB2194145B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/731Cellulose; Quaternized cellulose derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • A61K2800/524Preservatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/54Polymers characterized by specific structures/properties
    • A61K2800/542Polymers characterized by specific structures/properties characterized by the charge
    • A61K2800/5424Polymers characterized by specific structures/properties characterized by the charge anionic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A liquid saliva replacement formulation comprises an aqueous solution of carboxymethylcellulose having a viscosity in the range 170-230 centipoise, a preservative which consists either of a mixture of methyl, ethyl and propyl p-hydroxybenzoate or 2-bromo-2-nitropropane 1,3-diol and a mixture of salts present in normal saliva in a buffer medium which is sufficient to maintain the formulation at a pH in the range 5.8-6.2. The formulation is especially suitable for delivery to the mouth via an atomiser.

Description

SPECIFICATION Saliva replacement formulations This invention relates to saliva replacement formulations. More particularly, the invention relates to saliva replacement formulations which can be delivered via an atomiser.
Reduced salivary flow leading to xerostomia 'dry mouth' is an uncomfortable and often a distressful condition. In many cases the intraoral mucosa is cracked, bleeding and sore and hence swallowing and speech can be difficult. The reduced flow also gives rise to a higher incidence of dental caries due to the lack of the mechanical washing effect of saliva in clearing the mouth of cariogenic sweet foods and also due to the lack of the normal buffering action of the saliva in maintaining pH levels in the tooth environment at the correct level. A further reason for the higher incidence of caries in persons suffering from dry mouth is that in order to make eating more comfortable, they often change to soft diets usually with a high sugar content.
Dry mouth is a fairly common condition and is associated with a number of conditions such Sjogren's syndrome and sarcoidosis and also with treatments such as therapeutic radiotherapy in the head and neck and prolonged medication with salivary depressant drugs.
A variety of mouth lubricants and saliva substitutes are available for prescribing by physicians and dentists. However, the action of most of these products is concerned with the substitution of the physical lubricating action of saliva and does not take into account the increased susceptibility of affected persons to dental caries (Kidd, E.A.M. and Joyston-Bechal, S. Research (1984) 18, p 155.
A further disadvantage of known saliva replacement formulations is that they are extremely thick and sticky and consequently are difficult to administer. Furthermore, the preservatives used do not always comply with the requirements of the National Drugs Advisory Board (NDAB).
One artificial saliva formulation currently in use is that sold under the Trade Name Oralube. The effective ingredient of Oralube for combating xerostomia is sodium carboxymethylcellulose of unspecified grade and viscosity. The preservative used is methyl phydroxybenzoate. The remainder of Oralube is made up of various salts required to simuiate normal saliva, flavouring agents and other additives and distilled water. Oralube is an ad lib medication which the patient administers by placing a few drops on the tip of the tongue as required. However, this form of administration, necessitated by the sticky nature of Oralube, leads to problems of bacterial contamination. The preservative used in Oralube-methyl phydroxybenzoate-has not been found to be effective in preventing bacterial contamination.Furthermore use of methyl p-hydroxybenzoate does not meet the requirements set down by the NDAB for an artifical saliva.
It is an object of the present invention to provide an improved saliva replacement forinulation which can be readily administered and which has good bactericidal activity.
Accordingly, the invention provides a liquid saliva replacement formulation comprising a carboxymethylcellulose having a viscosity in the range 170-230 centipoise (mPas), a preservative selected from a mixture of methyl, ethyl and propyl phydroxybenzoate and 2-bromo-2-nitropropane 1,3-diol in association with a buffer medium sufficient to maintain the formulation at a pH in the range 5.8-6.2 and containing a mixture of salts present in normal saliva.
Preferably, the carboxymethylcellulose used is sodium carboxymethylcellulose. A particularly preferred form of sodium carboxymethylcellulose for use in the formulation according to the invention is a form sold under the Trade Mark 7H3SF. The carboxymethylcellulose is preferably used at a concentration in the range 0.5-7.5% w/v.
A preferred mixture of methyl, ethyl and propyl phydroxybenzoate for use as the preservative is that sold under the Trade Mark Nipasept Sodium. 2-Bromo-2-nitropropane 1,3-diol which can also be used as the preservative in the formulation according to the invention is sold under the Trade Mark Bronopol.
The preservative is preferably used at a concentration in the range 0.15-0.22% w/v.
The formulation according to the invention will preferably have a pH of 6.0.
The formulation according to the invention preferably contains fluoride in an amount effective to combat the formation of dental caries. Accordingly, a fluoride-containing formulation according to the invention will increase the resistance of the teeth to dental caries. Hence, as well as alleviating the pain and discomfort associated with xerostomia such a formulation will prevent the development of dental caries which invariably adds to the distress of xerostomia.
The liquid formulations of the invention can be administered by an atomiser because of their low viscosity. Thus they are easy to administer and economical to use. Administering the formulation according to the invention via an atomiser reduces the problems of bacterial contamination. Suitably, the formulation according to the invention will be filled into plastics containers of 60ml capacity fitted with a conventional atomiser.
It is found that the preservatives specified for use in the formulation according to the invention provide enhanced resistance to bacterial contamination.
The formulation may also include various additives, such as flavouring agents, colouring agents and non-sugar sweetening agents. An example of a non-sugar sweetening agent is sorbitol.
A typical formulation of the invention is as follows.
Ingredients Quantity per batch Nipasept Sodium 1.8 kg.
Sodium carboxymethylcellulose B.P. 5.85 kg.
Potassium chloride B.P. 562.5 g.
Magnesium chloride B.P. 52.92 g.
Calcium chloride B.P. 149.58 g.
Dipotassium hydrogen phosphate U.S.P. 723.42 g.
Potassium Dihydrogen phosphate N.F. 329.58 g.
Sodium fluoride B.P. 3.87 g.
Orange Flavour I.F.F. XV-1997 900 ml.
Carmosine C.I. 14720 18 g.
Sorbitol B.P. 70% (non-crystallising grade) 38.52 ky.
Purified Water B.P. to produce 900 litres Batch Size: 900 litres Approximately 500 litres of the purified water were placed in a calibrated plastics tank. The water was heated with slow but continuous stirring to 60"C. The various ingredients were added siowly with continuous stirring, beginning with the Nipasept Sodium. Finally, the volume was brought to 900 litres by adding the remaining purified water.
The formulation as prepared was filled into 60ml plastics containers fitted with a conventional atomiser. The plastics containers contain instructions for use, the patient being advised simply to spray the formulation directly into the mouth as required.
The remineralising capacity of the above formulation was compared with that of two commercially available saliva substitutes for patients with xerostomia. The commercial solutions tested were Glandosane (Trade Mark) (Dylade), which is based on carboxymethylcellulose and Saliva Orthana (Trade Mark) (Nyegaard) based on porcine mucin. Each of the formulations tested contained calcium and phosphate ions but only the formulation of the invention and Saliva Orthana contained fluoride. Laboratory made artificial saliva (Birkland, J.M., Caries Res. 7 11-18 1973) was used as a control. Artificial caries-like lesions were created on sound- buccal surfaces of 10 extracted premolar teeth. Four iongitudinal ground sections, 100 tjm thick, were prepared through each lesion and examined histologicaily in polarized light, qualitatively and quantitatively.
Each section was then varnished to expose only the outer surface of the lesion One section from each tooth was placed in each solution for 48 hours, solutions being changed Once after 24 hours. Histological examination at the end of the experiment showed significant remineralisation with Saliva Orthana and the formulation of the invention throughout the lesion, while the laboratory artifical saliva only remineralised the surface. However, with Glandosane the deeper parts of the lesion showed significant demineralisation due possibly to the C02 propellant in this spray.

Claims (10)

1. A liquid saliva replacement formulation comprising a carboxymethylcellulose having a viscosity in the range 170-230 centipoise (mPas), a preservative selected from a mixture of methyl, ethyl and propyl Rhydroxybenzoate and 2-bromo-2-nitropropane 1,3-diol in association with a buffer medium sufficient to maintain the formulation at a pH in the range 5.8-6.2 and containing a mixture of salts present in normal saliva.
2. A formulation according to Claim 1, which contains the carboxymethylcellulose at a concentration in the range 0.57.5% w/v.
3. A formulation according to Claim 1 or 2, which contains a sodium salt of carboxymethylcel lulose.
4. A formulation according to any one of Claims 1 to 3, wherein the preservative is a mixture of methyl, ethyl and propyl phydroxybenzoate.
5. A formulation according to any one of Claims 1 to 3, wherein the preservative is 2-bromo2-nitropropane 1,3-diol.
6. A formulation according to any preceding claim, wherein the preservative is usea at a concentration in the range 0.15--0.229/0 w/v.
7. A formulation according to any preceding claim, which has a pH of 6.0.
8. A formulation according to any preceding claim which contains fluoride in an amount effective to combat the formation of dental caries.
9. A formulation according to any preceding claim which contains one or more additional components selected from a flavouring agent, a colouring agent, and a nonsugar sweetening agent.
10. A formulation according to Claim 1, substantially as hereinbefore described with particular reference to the accompanying Formulation Example.
GB8703511A 1986-08-25 1987-02-16 Saliva replacement formulations Expired - Fee Related GB2194145B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE227186A IE58858B1 (en) 1986-08-25 1986-08-25 Saliva replacement formulations

Publications (3)

Publication Number Publication Date
GB8703511D0 GB8703511D0 (en) 1987-03-25
GB2194145A true GB2194145A (en) 1988-03-02
GB2194145B GB2194145B (en) 1990-08-01

Family

ID=11033849

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8703511A Expired - Fee Related GB2194145B (en) 1986-08-25 1987-02-16 Saliva replacement formulations

Country Status (3)

Country Link
GB (1) GB2194145B (en)
IE (1) IE58858B1 (en)
ZA (1) ZA871132B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020971A1 (en) * 1994-02-02 1995-08-10 Stichting Voor De Technische Wetenschappen Therapeutic composition for replacing and/or supplementing body fluids
WO2006013081A1 (en) * 2004-08-02 2006-02-09 Glaxo Group Limited Novel composition for xerostomia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
G.B. THE EXTRA PHARMACOPOEIA (1982)}CARMELLOSE SODIUM} *
GB THE BRITISH NATIONAL FORMULARY, (1985) *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020971A1 (en) * 1994-02-02 1995-08-10 Stichting Voor De Technische Wetenschappen Therapeutic composition for replacing and/or supplementing body fluids
NL9400160A (en) * 1994-02-02 1995-09-01 Stichting Tech Wetenschapp Therapeutic composition for the replacement and / or replenishment of body fluids.
WO2006013081A1 (en) * 2004-08-02 2006-02-09 Glaxo Group Limited Novel composition for xerostomia
US9044500B2 (en) 2004-08-02 2015-06-02 Glaxosmithkline Consumer Healthcare Gmbh & Co Kg Composition for xerostomia
US10350238B2 (en) 2004-08-02 2019-07-16 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Method of treating xerostomia

Also Published As

Publication number Publication date
GB2194145B (en) 1990-08-01
ZA871132B (en) 1987-08-11
IE58858B1 (en) 1993-11-17
IE862271L (en) 1988-02-25
GB8703511D0 (en) 1987-03-25

Similar Documents

Publication Publication Date Title
US4233288A (en) Gum emulsified liquid package for delivering and preserving liquid content in the mouth
Diaz-Arnold et al. The impact of saliva on patient care: A literature review
FI104044B (en) Preparation used for dental care
CA1326212C (en) Salivary stimulant
OLSSON et al. Objective and subjective efficacy of saliva substitutes containing mucin and carboxymethylcellulose
EP0396634B1 (en) Method for treating xerostomia employing chewing gum
Walsh Preventive dentistry for the general dental practitioner
JP2001500874A (en) Mouthwash consisting of calcium and phosphate ions in supersaturated solution
JP2007145847A (en) Anti-caries chewing gum, candy, gel, toothpaste and dentifrice
IE87094B1 (en) Gel comprising chlorhexidine
US11654127B2 (en) Composition for use in the prevention and/or treatment of Oncologic Treatment Induced Orogastrointestinal Mucositis
WO2000056344A1 (en) Artificial saliva
US20060078620A1 (en) Oil composition based on peroxidised lipids, which can be used in the treatment of xerostomia
NO178527B (en) Process for the preparation of a medicament for oral administration of fluoride ion
GB2194145A (en) Saliva replacement formulations
EP3043783B1 (en) Lubricating complex for the mouth
CN1173323A (en) Composition for enhancing oral hygiene
Ferguson et al. Saliva substitutes in the management of salivary gland dysfunction
Vissink et al. Xerostomia and dental problems in the head and neck radiation patient
JP4909809B2 (en) Artificial saliva
JP4804420B2 (en) Artificial saliva
DE202005014019U1 (en) Composition for use as a saliva substitute and for treating dryness of the mouth and throat comprises carrageenan or alginate
Stavreva et al. XEROSTOMIA, ETIOLOGY, DENTAL IMPLICATIONS AND PROSTHODONTIC MANAGEMENT.
RU2838592C2 (en) Medicinal product for prevention and symptomatic treatment of xerostomia
Mujib et al. Chewing gum and oral health

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee